Guillain-Barré Syndrome and Healthcare Needs during Zika Virus Transmission, Puerto Rico, 2016

Emilio Dirlikov, Krista Kniss, Chelsea Major, Dana Thomas, Cesar A. Virgen, Marrielle Mayshack, Jason Asher, Luis Mier-y-Teran-Romero, Jorge L. Salinas, Daniel M. Pastula, Tyler M. Sharp, James Sejvar, Michael A. Johansson, Brenda Rivera-Garcia

To assist with public health preparedness activities, we estimated the number of expected cases of Zika virus in Puerto Rico and associated healthcare needs. Estimated annual incidence is 3.2–5.1 times the baseline, and long-term care needs are predicted to be 3–5 times greater than in years with no Zika virus.

Guillain-Barré syndrome (GBS) is an autoimmune disorder characterized by varying degrees of weakness, sensory abnormalities, and autonomic dysfunction due to peripheral nerve or nerve root damage (1). Annual GBS incidence worldwide is ≈1.1–1.8 cases/100,000 population and varies by geography and age group (2,3). Death is rare and is usually caused by respiratory failure, autonomic dysfunction, or deep vein thrombosis (4).

GBS has been associated with various infectious agents, including Zika virus (5). Zika virus is a flavivirus transmitted primarily by Aedes species mosquitoes; symptoms of infection include rash, arthralgia, and fever (6). During a 2013–2014 outbreak in French Polynesia, 42 cases of GBS were reported during a 7-month period, compared with 3–10 cases annually in previous years; all GBS patients during the outbreak had Zika virus antibodies (7).

In December 2015, the Puerto Rico Department of Health reported local transmission of Zika virus (8). In February 2016, the Department of Health reported the first case of Zika virus–associated GBS and established the GBS Passive Surveillance System, with support from the Centers for Disease Control and Prevention (9). During January 1–July 31, 2016, a total of 56 cases of GBS were reported; evidence of Zika virus or flavivirus infection was found in 34 (61%) of these (9). As in other locations (5), GBS cases in Puerto Rico are anticipated to increase with ongoing Zika virus transmission. To assist with public health preparedness activities, we estimated the annual number of expected cases of GBS and associated healthcare needs in Puerto Rico (online Technical Appendix, http://wwwnc.cdc.gov/EID/article/23/1/16-1290-Techapp1.pdf).

The Study
We estimated the weekly number of cases of GBS and associated healthcare needs for 3 scenarios: 1) in the absence of Zika virus transmission; 2) in an average week during Zika virus transmission; and 3) during the peak week of Zika virus transmission (Table). Estimates were derived from baseline and Zika virus–associated GBS cases. The population of Puerto Rico in 2015 was estimated at 3,474,182 persons (10).

We calculated baseline GBS incidence in Puerto Rico by using data collected through medical chart review of patients suspected to have GBS at 9 reference hospitals in Puerto Rico during 2012–2015 and for whom neurologic diagnosis was confirmed by the Brighton Collaboration criteria (11). The 2013 incidence of GBS was 1.7 cases (95% CI 1.3–2.1 cases) per 100,000 population (J.L. Salinas, unpub. data). Using this incidence range, in the absence of Zika virus transmission, we estimated that 1 (interquartile range [IQR] 0–2) case occurs each week, and 59 (IQR 52–66) cases occur each year.

We assumed that, during Zika virus transmission, ≈25% of the population could have been infected during 2016, similar to recent chikungunya and dengue virus epidemics in Puerto Rico (12). We used a triangular distribution to characterize uncertainty, with a minimum estimate of 10% infected and a maximum estimate of 70% infected (12,13). Estimated GBS risk associated with Zika virus infection was assumed to be 1.1–2.3 cases/10,000 infections on the basis of a separate analysis of data aggregated from French Polynesia (7), Yap (13), Brazil (14), Colombia, El Salvador, Honduras, the Dominican Republic, and Puerto Rico (L. Mier-y-Teran, unpub. data). We used Monte Carlo sampling to draw 1 million...
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 1, January 2017

≈10 (IQR 5–15) new patients would need treatment with IVIg, and 2 (IQR 1–4) new patients would require mechanical ventilation. An estimated 6 (IQR 3–10) new patients would require a regular ward bed, whereas 4 (IQR 2–7) new patients would require an ICU bed.

An estimated 0 (IQR 0–1) patients would require long-term care during a week without Zika virus transmission, 2 (IQR 1–3) patients during an average week of Zika virus transmission, and 5 (IQR 2–8) patients during the peak week. During 2016, ≈108 (IQR 85–138) GBS patients would require long-term care.

Conclusions
We estimated that there would be 191–305 new cases of GBS in Puerto Rico in 2016, comprising baseline and Zika virus–associated cases. This estimate represents an annual incidence of 5.5–8.7 cases/100,000 population, which is 3.2–5.1 times the baseline incidence. Associated healthcare resource needs will increase accordingly. Estimated long-term care needs in 2016 were predicted to be 3–5 times greater than in years with no Zika virus transmission.

These estimates have limitations. First, there is considerable uncertainty around key assumptions, including that increases in GBS incidence will mirror those experienced in other Zika virus–affected countries (5,7,13,14). Second, the estimates of associated healthcare needs did not address all possible needs, such as alternative treatments (i.e., plasmapheresis) or additional treatments, such as those for neuropathic pain, cardiac arrhythmias, and deep vein thrombosis. Third, estimates assumed 1 peak week, although GBS cases tend to cluster, and multiple peaks could occur. Finally, a causal association between Zika virus infection and GBS has not been definitively established.

Table. Estimates of weekly Guillain-Barré syndrome cases and healthcare resource needs, Puerto Rico, 2016

| Variable                                      | Scenario*                     | Estimate | Median | Interquartile range | 95% Uncertainty interval |
|-----------------------------------------------|-------------------------------|----------|--------|--------------------|-------------------------|
| New cases and long-term care patients         |                               |          |        |                    |                         |
| Case-patients                                 | No Zika virus                 | 1        | 0–2    | 0–4                |                         |
|                                               | Average week during Zika virus| 5        | 3–6    | 1–11               |                         |
|                                               | Peak week during Zika virus   | 11       | 6–17   | 1–34               |                         |
| Long-term care patients                       |                               |          |        |                    |                         |
| Case-patients                                 | No Zika virus                 | 0        | 0–1    | 0–2                |                         |
|                                               | Average week during Zika virus| 2        | 1–3    | 0–6                |                         |
|                                               | Peak week during Zika virus   | 5        | 2–8    | 0–16               |                         |
| New patient healthcare resource needs         |                               |          |        |                    |                         |
| Intravenous immunoglobulin                    | No Zika virus                 | 1        | 0–2    | 0–3                |                         |
|                                               | Average week during Zika virus| 4        | 3–6    | 0–10               |                         |
|                                               | Peak week during Zika virus   | 10       | 5–15   | 0–30               |                         |
| Mechanical ventilation                        | No Zika virus                 | 0        | 0–0    | 0–1                |                         |
|                                               | Average week during Zika virus| 1        | 0–2    | 0–3                |                         |
|                                               | Peak week during Zika virus   | 2        | 1–4    | 0–8                |                         |
| Regular ward beds                             | No Zika virus                 | 0        | 0–1    | 0–3                |                         |
|                                               | Average week during Zika virus| 3        | 1–4    | 0–7                |                         |
|                                               | Peak week during Zika virus   | 6        | 3–10   | 0–21               |                         |
| Intensive care unit beds                      | No Zika virus                 | 0        | 0–1    | 0–2                |                         |
|                                               | Average week during Zika virus| 2        | 1–3    | 0–6                |                         |
|                                               | Peak week during Zika virus   | 4        | 2–7    | 0–15               |                         |

*The weekly number of Guillain-Barré syndrome cases and associated healthcare needs were estimated for 3 scenarios: 1) in the absence of Zika virus transmission; 2) in an average week during Zika virus transmission; and 3) during the peak week of Zika virus transmission.
Continued GBS surveillance will monitor for increased incidence and enable adapted public health response. Healthcare workers, including internists, family physicians, and nurses, might need training to ensure adequate patient clinical management if GBS cases increase as predicted. The Puerto Rico Department of Health and the Centers for Disease Control and Prevention have developed training material toward this end. The availability and accessibility of GBS treatment, especially IVIg, and long-term care services should be evaluated, especially given the high costs of GBS patient care (15). The Puerto Rico Department of Health is also creating an inventory of available and expandable resources, working with manufacturers and distributors to understand supply chains, and facilitating prompt treatment delivery at points of care.

Dr. Dirlikov is a Centers for Disease Control and Prevention Epidemic Intelligence Service Officer posted to the Puerto Rico Department of Health and serves as the GBS team lead for the coordinated Zika response. His areas of interest are infectious diseases, surveillance, and global health.

References

1. Yuki N, Hartung H-P. Guillain-Barré syndrome. N Engl J Med. 2012;366:2294–304. http://dx.doi.org/10.1056/NEJMra1114525
2. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33. http://dx.doi.org/10.1159/000324710
3. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide: A systematic literature review. Neuroepidemiology. 2009;32:150–63. http://dx.doi.org/10.1159/000184748
4. Hund EF, Borel CO, Comblath DR, Hanley DF, McKhann GM. Intensive management and treatment of severe Guillain-Barré syndrome. Crit Care Med. 1993;21:433–46. http://dx.doi.org/10.1097/00003246-199303000-00023
5. dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, et al. Zika virus and the Guillain-Barré syndrome—case series from seven countries. N Engl J Med. 2016;NEJMc1609015. http://dx.doi.org/10.1056/NEJMc1609015
6. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. N Engl J Med. 2016;374:1552–63. http://dx.doi.org/10.1056/NEJMra1602113
7. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387:1531–9. http://dx.doi.org/10.1016/S0140-6736(16)00562-6
8. Thomas DL, Sharp TM, Torres J, Armstrong PA, Munoz-Jordan J, Ryff KR, et al. Local Transmission of Zika Virus—Puerto Rico, November 23, 2015-January 28, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:154–8. http://dx.doi.org/10.15585/mmwr.mm6506e2
9. Dirlikov E, Major CG, Mayshack M, Medina N, Matos D, Ryff KR, et al. Guillain-Barré syndrome during ongoing Zika virus transmission—Puerto Rico, January 1–July 31, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:910–4. http://dx.doi.org/10.15585/mmwr.mm6534e1
10. US Census Bureau. Puerto Rico commonwealth totals: vintage 2015 [cited 2016 May 9]. http://www.census.gov/popest/data/puerto_rico/totals/2015/index.html
11. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al.; Brighton Collaboration GBS Working Group. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. http://dx.doi.org/10.1016/j.vaccine.2010.06.003
12. Chiu CY, Bres V, Yu G, Krysztof D, Naccache SN, Lee D, et al. Genomic assays for identification of chikungunya virus in blood donors, Puerto Rico, 2014. Emerg Infect Dis. 2015;21:1409–13. http://dx.doi.org/10.3201/eid2108.150458
13. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43. http://dx.doi.org/10.1056/NEJMoa0805715
14. Cardoso CW, Paploski IA, Kikuti M, Rodrigues MS, Silva MM, Campos GS, et al. Outbreak of exanthematous illness associated with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerg Infect Dis. 2015;21:2274–6. http://dx.doi.org/10.3201/eid2112.151167
15. Frenzen PD. Economic cost of Guillain-Barré syndrome in the United States. Neurology. 2008;71:21–7. http://dx.doi.org/10.1212/01.wnl.0000316395.54258.d1

Address for correspondence: Emilio Dirlikov, Departamento de Salud, Oficina de Epidemiología e Investigación, PO Box 70184, San Juan, PR 00936-8184, USA; email: GBS@salud.pr.gov
Guillain-Barré Syndrome and Healthcare Needs during Zika Virus Transmission, Puerto Rico, 2016

Technical Appendix

Methods

We used Monte Carlo sampling with 1 million realizations to estimate case numbers and resources required. Each realization drew a value of the Guillain-Barré syndrome (GBS) baseline risk, the risk for Zika virus infection, the risk of GBS after Zika virus infection, and the relative incidence at the peak compared with an average week from the distributions specified in the previous section. Once these parameters were selected, the different components of our model were obtained as follows:

**Total Number of Baseline and Zika Virus–Associated GBS Cases**

The number of baseline GBS cases during the outbreak was sampled from a binomial process for the population of Puerto Rico with a probability equal to the baseline rate, assuming a time span of 1 year. The total number of Zika virus–associated GBS cases during the outbreak was sampled from a binomial process for the population of Puerto Rico with a probability equal to the product of the attack rate and the GBS risk after a Zika virus infection.

**Number of Weekly Baseline GBS Cases in the Absence of Zika Virus**

The mean number of weekly baseline GBS cases was sampled from a Poisson process with a mean equal to the total number of baseline GBS cases divided by 52, the number of weeks in a year.

**Number of Zika Virus–Associated GBS Cases in an Average Week and Peak Week during Zika Virus Transmission**

The mean number of weekly Zika virus–associated GBS cases was sampled from a Poisson process with a mean equal to the total number of Zika virus–associated cases divided by
the outbreak duration in weeks (52, the assumed length of the epidemic). The mean number of weekly Zika virus–associated GBS cases in the peak week was sampled by using a Poisson process. The mean was equal to the average number of Zika virus–associated cases per week multiplied by the relative sampled incidence at peak compared with an average week.

**Resource Needs for GBS Patients**

For each weekly estimate of cases, we estimated the proportion requiring different levels of healthcare from a binomial process with the respective probability (Technical Appendix Table) and the number of estimated cases.

**Code**

Estimates were generated using R (1). The following code was used:

```r
rm(list = ls())
require(data.table)
require(dplyr)
require(triangle)
set.seed(8675309)
n_samples <- 1e6
### fixed parameters
PR_population <- 3474182
GBS_long_term_care_fraction <- 0.45
GBS_IVIG_fraction <- 0.9
GBS_novent_ICU_fraction <- 0.2
GBS_vent_ICU_fraction <- 0.2
GBS_hosp_nonICU_fraction <- 0.6
zika_outbreak_duration_weeks <- 52
### simulation table
sim.data <- data.table(
```
GBS_baseline_rate = rnorm(n_samples, 1.7e-5, 0.2e-5),

zika_attack_rate = rtriangle(n_samples, 0.1, 0.7, 0.25),

GBS_zika_rate = rnorm(n_samples, 1.6e-4, 0.31e-4),

peak_mean_weekly_incidence_ratio = runif(n_samples, 2, 4)

) %>%
mutate(

  GBS_total_background_cases =
  rbinom(n_samples, PR_population, GBS_baseline_rate),

  GBS_weekly_background_cases_mean =
  rpois(n_samples, GBS_total_background_cases / zika_outbreak_duration_weeks),

  GBS_total_zika_cases =
  rbinom(n_samples, PR_population, zika_attack_rate * GBS_zika_rate),

  GBS_weekly_zika_cases_mean =
  rpois(n_samples, GBS_total_zika_cases / zika_outbreak_duration_weeks),

  GBS_total_cases = GBS_total_zika_cases + GBS_total_background_cases,

  GBS_weekly_cases_mean = GBS_weekly_zika_cases_mean +
GBS_weekly_background_cases_mean,

  GBS_weekly_cases_peak = GBS_weekly_background_cases_mean +
  rpois(n_samples, GBS_weekly_zika_cases_mean * peak_mean_weekly_incidence_ratio),

  GBS_total_cases_long_term = rbinom(n_samples, GBS_total_cases, GBS_long_term_care_fraction),

  GBS_total_cases_background_long_term = rbinom(n_samples, GBS_total_background_cases, GBS_long_term_care_fraction)
get_resource_needs = function(GBS_weekly_cases) {
  output = rbind(
    data.table(Resource = “Cases per Week,”
                 Value = GBS_weekly_cases),
    data.table(Resource = “Long-Term Care Patients,”
                 Value = rbinom(n_samples, GBS_weekly_cases, GBS_long_term_care_fraction)),
    data.table(Resource = “Ventilators,”
                 Value = rbinom(n_samples, GBS_weekly_cases, GBS_vent_ICU_fraction)),
    data.table(Resource = “IVIg per Week,”
                 Value = rbinom(n_samples, GBS_weekly_cases, GBS_IVIG_fraction)),
    data.table(Resource = “Non-ICU Beds,”
                 Value = rbinom(n_samples, GBS_weekly_cases, GBS_hosp_nonICU_fraction)),
    data.table(Resource = “ICU Beds,”
                 Value = rbinom(n_samples, GBS_weekly_cases,
                               GBS_novent_ICU_fraction + GBS_vent_ICU_fraction)))
  return(output)
}

raw_weekly_resources <- rbind(
cbind(get_resource_needs(sim.data$GBS_weekly_background_cases_mean),
      Estimate = “No Zika”),
cbind(get_resource_needs(sim.data$GBS_weekly_cases_mean),
      Estimate = “Average Zika”),
cbind(get_resource_needs(sim.data$GBS_weekly_cases_peak),
      Estimate = “Peak Zika”)
Estimate = "Peak Zika") %>%
mutate(
Estimate = factor(Estimate, c("No Zika," "Average Zika," "Peak Zika"),
Resource = factor(Resource, c("Cases per Week," "Long-Term Care Patients,"
"IVIg per Week," "Ventilators," "Non-ICU Beds," "ICU Beds")))
### summarize
summarized_data <- raw_weekly_resources %>%
as.data.frame() %>%
group_by(Resource, Estimate) %>%
do(
quantile_frame =
data.frame(t(quantile(.Value, probs = c(0.025, 0.25, 0.5, 0.75, 0.975))))
colnames(quantile_frame) = c("Low," "IQR_Low," "Mid," "IQR_High," "High")
return(quantile_frame)
}) %>%
mutate(
Median = signif(Mid, 2),
IQR = paste0(signif(IQR_Low, 2), "–", signif(IQR_High, 2)),
`95% UI` = paste0(signif(Low, 2), "–", signif(High, 2))) %>%
select(Resource, Estimate, Median, IQR, `95% UI`) %>%
arrange(Resource, Estimate)
summarized_data[]
References

1. R Project. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016.

2. US Census Bureau. Puerto Rico commonwealth totals: vintage 2015 [cited 2016 May 9].
http://www.census.gov/popest/data/puerto_rico/totals/2015/index.html

3. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43.
http://dx.doi.org/10.1056/NEJMoA0805715

4. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43.
http://dx.doi.org/10.1056/NEJMoA0805715

5. Cardoso CW, Paploski IA, Kikuti M, Rodrigues MS, Silva MM, Campos GS, et al. Outbreak of exanthematous illness associated with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerg Infect Dis. 2015;21:2274–6. http://dx.doi.org/10.3201/eid2112.151167
**Technical Appendix Table.** Parameters used in the model for a study of Guillain-Barré syndrome and healthcare needs during Zika virus transmission, Puerto Rico, 2016*  

| Parameter                                                                 | Estimated value                  | Distribution       | Source                                                                 | Citation                      |
|---------------------------------------------------------------------------|----------------------------------|--------------------|------------------------------------------------------------------------|-------------------------------|
| Puerto Rico population, 2016                                             | 3,474,182                        | Fixed              | US Census                                                              | US Census (2)                 |
| Baseline GBS rate                                                        | 1.7/100,000 population/year      | Gaussian, $\sigma = 0.20$ | Chart review of Puerto Rico GBS patients Historic CHIKV and DENV epidemics in Puerto Rico | (J.L. Salinas, unpub. data)    |
| Zika virus infection risk in Puerto Rico, 2016                           | 25% peak probability             | Triangle, min 10%, max 70% | Historic CHIKV and DENV epidemics in Puerto Rico | (3)                          |
| Fraction of Zika virus infections developing GBS                         | 1.6/10,000 infections            | Gaussian, $\sigma = 0.31$ | Analysis of country-level GBS and Zika virus reports                  | (L. Mier-y-Teran, unpub. data) |
| Relative Zika virus incidence during peak week compared with an average week | 2–4 times                        | Uniform            | Analysis of country-level GBS and Zika virus reports                  | (L. Mier-y-Teran, unpub. data) |
| Percentage of GBS patients needing long-term care                        | 45                               | Fixed              | Chart review of Puerto Rico GBS patients                              | (J.L. Salinas, unpub. data)    |
| Percentage of GBS patients needing IVIg                                   | 90                               | Fixed              | Chart review of Puerto Rico GBS patients                              | (J.L. Salinas, unpub. data)    |
| Percentage of GBS patients needing an ICU bed                            | 40                               | Fixed              | Chart review of Puerto Rico GBS patients                              | (J.L. Salinas, unpub. data)    |
| Percentage of GBS patients needing an ICU bed and a ventilator           | 20                               | Fixed              | Chart review of Puerto Rico GBS patients                              | (J.L. Salinas, unpub. data)    |
| Percentage of GBS patients needing an ICU bed but no ventilator          | 20                               | Fixed              | Chart review of Puerto Rico GBS patients                              | (J.L. Salinas, unpub. data)    |
| Percentage of GBS patients needing a regular ward bed                     | 60                               | Fixed              | Chart review of Puerto Rico GBS patients                              | (J.L. Salinas, unpub. data)    |

*CHIKV, chikungunya virus; DENV, dengue virus; GBS, Guillain-Barré syndrome; ICU, intensive care unit; IVIg, intravenous immunoglobulin.